DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
DexCom (DXCM) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
by Zacks Equity Research
Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.
Medical Devices ETF Hits 52-Week High: Stocks to Watch
by Bryan Hayes
Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.
Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek
by Zacks Equity Research
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.
DexCom (DXCM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.
Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost
by Zacks Equity Research
Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System
by Zacks Equity Research
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?
by Zacks Equity Research
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Ambrx Biopharma Inc. (AMAM) have performed compared to their sector so far this year.
Investors Heavily Search DexCom, Inc. (DXCM): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.
DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DaVita (DVA) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
DaVita (DVA) Expands Operational Footprint Via New Agreement
by Zacks Equity Research
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
DexCom (DXCM) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $121.78 in the latest trading session, marking a -0.43% move from the prior day.
DexCom (DXCM) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio
by Zacks Equity Research
Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is DexCom (DXCM) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.